Relevant bibliographies by topics / Matthew 6:9-13 / Journal articles
To see the other types of publications on this topic, follow the link: Matthew 6:9-13.

Journal articles on the topic 'Matthew 6:9-13'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Matthew 6:9-13.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jung, Chang-Wook. "Quotation of Isaiah 6:9-10 in Matthew 13:14-15." Journal of Biblical Text Research 26 (April 30, 2010): 137–54. http://dx.doi.org/10.28977/jbtr.2010.4.26.137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gibson, Jeffrey B. "Matthew 6:9–13//Luke 11:2–4: An Eschatological Prayer?" Biblical Theology Bulletin: Journal of Bible and Culture 31, no. 3 (2001): 96–105. http://dx.doi.org/10.1177/014610790103100304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Eagy, Ryan. "Matthew 9:9–17 and the Divine Bridegroom of Hosea." Expository Times 128, no. 11 (2017): 521–28. http://dx.doi.org/10.1177/0014524617701569.

Full text
Abstract:
Jesus’s use of the bridegroom imagery is usually connected to the divine bridegroom in the OT through systematic or biblical theological categories. This article argues that Matthew’s use of Hosea 6:6 in Matt 9:13 is an indicator that readers should understand Jesus’s bridegroom metaphor in Matt 9:15 as a claim to occupying the same role as the divine bridegroom of Hos 2:16. By following two lines of reasoning—the unity of Matt 9:9–17 and the literary and textual connections between Hos 6:6 and Hos 2:16—this paper will seek to demonstrate this high Christological claim was intentional in Matth
APA, Harvard, Vancouver, ISO, and other styles
4

Kubiś, Adam. "“I delight in love, not in sacrifice”: Hosea 6:6 and Its Rereading in the Gospel of Matthew." Collectanea Theologica 90, no. 5 (2021): 295–320. http://dx.doi.org/10.21697/ct.2020.90.5.12.

Full text
Abstract:
The first part of the article deals with four different understandings of Hosea 6:6 in the context of that entire book: (1) the repudiation of the cult as such; (2) the rejection of a particular notion of cult; (3) the priority of ethics over the cult; and (4) the symbiosis of cult and ethics, i.e. that an authentic cult interweaves ethical values and proper ritual conduct. The author concludes that the fourth interpretation best fits the message of the Book of Hosea. The second part of the article deals with the problem of the textual Vorlage which would have been used by Matthew. He seems to
APA, Harvard, Vancouver, ISO, and other styles
5

Артюшин, Филофей. "Under the Sign of Mercy (Mt. 9, 9-13): The Problem of the Relationship Between Righteousness and Sin in the Theological Context of the Gospel of Matthew." Библия и христианская древность, no. 4(12) (December 15, 2021): 111–30. http://dx.doi.org/10.31802/bca.2021.12.4.005.

Full text
Abstract:
В статье проводится экзегетический анализ эпизода призвания ап. Матфея и его ближайшего контекста: трапеза с мытарями и грешниками и диспут о посте (см. Мф. 9, 9 - 13, 14-17). На основании практического применения методологии нарративного анализа выявляется структура, литературный жанр (диспут), динамика сюжетного развития, а также содержательные особенности данного евангельского пассажа. В методологической канве историко-критического и редакционно-богословского анализа выявляется богословская проблематика эпизода в свете соотношения категорий праведности и греха. Результаты формального анализ
APA, Harvard, Vancouver, ISO, and other styles
6

Herok, Piotr. "Summary Statements in the Gospel of Matthew." Biblical Annals 13, no. 4 (2023): 617–33. http://dx.doi.org/10.31743/biban.14912.

Full text
Abstract:
This article examines the summary statements in the first gospel. The investigation aims to establish a precise set of Matthean texts belonging to this literary genre. Following a presentation of a variety of solutions (R. Schnackenburg, J. Gnilka, E. Schweizer, D.A. Hagner, R.H. Gundry, J. Nolland, A. Paciorek, U. Luz, R.T. France, W.D. Davies and D.C. Allison, C.S. Keener, G.R. Osborne, C.A. Evans, S. Grasso, W. Egger, B. Gerhardsson, L. Novakovic), literary considerations are examined against the background of various scholarly propositions, giving precise criteria to denote a given gospel
APA, Harvard, Vancouver, ISO, and other styles
7

CHEONG, Chong-Seong. "Understanding Human Suffering and Jesus Prayer (Matthew 6:9-13) －In View of Asian Yangdanjõk (兩端的) Wisdom in Epistemology". Korean New Testament Studies 27, № 1 (2020): 33–78. http://dx.doi.org/10.31982/knts.2020.03.27.1.33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Baynham, Thomas L. "Our father, who art in heaven: The importance of the Lord’s Prayer in congregational song." Review & Expositor 118, no. 4 (2021): 529–35. http://dx.doi.org/10.1177/00346373221100682.

Full text
Abstract:
The Lord’s Prayer is known to many, even as early as childhood those, who can and do recite it from memory. It is prayed often in the context of worship settings: regular corporate worship, as well as funerals and weddings. The “Our Father,” as the prayer is often called, is perhaps the most well-known prayer in the Christian faith, yet what many have learned to recite from memory is not consistent with what is recorded in Scripture. The intent of this article is twofold. The first section offers a brief interpretation of the prayer, using the KJV translation of the Matthew text (6:9–13) plus
APA, Harvard, Vancouver, ISO, and other styles
9

Лазаренко, Нил. "Theological and Exegetical Foundations of some Translation Solutions in BTD (Based on the Gospel of Matthew)." Theological Herald, no. 4(39) (December 15, 2020): 35–47. http://dx.doi.org/10.31802/gb.2020.39.4.002.

Full text
Abstract:
В 2018 г. вышел в свет новый перевод Четвероевангелия на немецкий язык, выполненный схиархимандритом Сербской Православной Церкви Иустином (Рауером). В статье анализируется ряд мест из Евангелия от Матфея. Будучи участником редакционной коммиссии перевода, автор статьи объясняет, какими соображениями руководствовался переводчик в тех или иных случаях, дает филологические и богословские основания переводческих решений, указывает на преимущества (или в одном случае - на недостаток) нового перевода в сравнении с другими переводами. Особое внимание уделяется тем местам, где немецкий перевод отлича
APA, Harvard, Vancouver, ISO, and other styles
10

Du Rand, Jan A. "Die doodstraf: ’n teologiese standpunt." Verbum et Ecclesia 26, no. 2 (2005): 341–56. http://dx.doi.org/10.4102/ve.v26i2.228.

Full text
Abstract:
The recent process of structural transformation on all levels of society in South Africa urges theological reflection to participate. In this instance the crucial issue of capital punishment is at stake. After a brief survey of viewpoints and arguments concerning the issue, prominent and mostly debated Biblical texts are analysed. Genesis 9:6 and Exodus 21:24, for example are read within their cultural frameworks and theological contexts. The same is done with Matthew 5:21-22; 15:4; 26:52; John 7:53-8:11 and Romans 13:1-7. The conclusion is that Old Testament references to capital punishment a
APA, Harvard, Vancouver, ISO, and other styles
11

Parsons, Heather, Sylvan Baca, Anthony D'Ippolito, et al. "Abstract PS06-07: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform." Cancer Research 84, no. 9_Supplement (2024): PS06–07—PS06–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps06-07.

Full text
Abstract:
Abstract Background: Tumor HER2 status remains a critical predictive biomarker for patients with breast cancer given the availability of highly effective anti-HER2 therapies. However, determination of HER2 status relies on a complex, tissue-dependent algorithm optimized for extremes of the phenotype – HER2+ vs HER2- status. Given the challenges in reliably obtaining informative tissue biopsies as disease progresses, the new therapeutic relevance of HER2-low breast cancer (IHC 1+ and FISH-negative IHC 2+), and the undependability of biomarkers in this range, better approaches are needed. Epigen
APA, Harvard, Vancouver, ISO, and other styles
12

Kaymakci, M., M. Elfishawi, H. Langenfeld, et al. "AB0781 LARGE VESSEL INVOLVEMENT IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1600.1–1601. http://dx.doi.org/10.1136/annrheumdis-2023-eular.292.

Full text
Abstract:
BackgroundAnti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [1]. There is limited knowledge about large vessel involvement in AAV (L-AAV); mainly described in case reports and small series. L-AAV can involve temporal arteries (TA-AAV), aorta (A-AAV), and periaortic soft tissue (PA-AAV).ObjectivesThe objective of this study was to investigate the characteristics of L-AAV.Me
APA, Harvard, Vancouver, ISO, and other styles
13

Fuentes, Gabriela, Maria J. Rodriguez, Matthew H. G. Katz, et al. "Abstract B002: Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)." Cancer Research 84, no. 2_Supplement (2024): B002. http://dx.doi.org/10.1158/1538-7445.panca2023-b002.

Full text
Abstract:
Abstract Patients with LAPC or BRPC often receive radiation therapy (RT) after chemotherapy (chemo) if no metastatic progression has occurred. Historically, CA19-9 normalizes in ~20 to 30% of patients after all therapy. While escalated dose radiotherapy (EDR) has shown promising survival in selected patients, extending use of EDR to all patients is challenging due to RT dose limitations of the bowel. To overcome this limitation, we are investigating NBTXR3, composed of functionalized hafnium oxide nanoparticles administered by a single intratumoral injection, locally amplifying the RT dose. In
APA, Harvard, Vancouver, ISO, and other styles
14

Goetz, Matthew, Vera J. Suman, Joel M. Reid, et al. "Abstract P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study." Clinical Cancer Research 31, no. 12_Supplement (2025): P1–11–04—P1–11–04. https://doi.org/10.1158/1557-3265.sabcs24-p1-11-04.

Full text
Abstract:
Abstract Background: Aromatase inhibition (AI) with ovarian function suppression (OFS) is standard for premenopausal women (PrW) with ER+/HER2- primary breast cancer (BC). However, > 40% are intolerant of OFS leaving tamoxifen (TAM) as their only option. In the neoadjuvant endocrine setting, PrW with endocrine sensitive disease (ESD) (week 4 Ki-67 ≤ 10%) have 5-year disease free survival > 97%; however, only 35% achieve ESD with TAM vs 76% with AI+OFS (Gluz SABCS 2023). Z-endoxifen (ENDX) is a selective estrogen receptor modulator targeting ERα at 3-5 ng/ml and PKCβ1 ≥ 500 ng/ml,
APA, Harvard, Vancouver, ISO, and other styles
15

Berdeja, Jesus, Sundar Jagannath, Jeffrey Zonder, et al. "Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study." Blood 124, no. 21 (2014): 2119. http://dx.doi.org/10.1182/blood.v124.21.2119.2119.

Full text
Abstract:
Abstract INTRODUCTION Renal impairment affects more than a third of patients with relapsed multiple myeloma (MM). Renal impairment predicts poor outcome with conventional treatments, while reversal of renal function is associated with improved outcome.1,2 Better therapies for patients with MM and renal impairment are needed. Elotuzumab (Elo) is a humanized monoclonal antibody targeted against Signaling Lymphocytic Activation Molecule F7 (SLAMF7; also called CS1). Through both direct activation and engagement of natural killer cells, Elo selectively kills SLAMF7-expressing myeloma cells and, in
APA, Harvard, Vancouver, ISO, and other styles
16

Cherednichenko, Oleksii, and Oleh Rybchynskyi. "THE RESTORATION PROGRAM OF THE WHITESTONE SCULPTURE OF YAN NEPOMUK OF THE BEGINNING 19-TH CENTURY FROM VILLAGE VELYKA VYSHENKA, YAVORIW DISTRIKT, LVIV REGION." Current Issues in Research, Conservation and Restoration of Historic Fortifications 16, no. 2022 (2022): 91–101. http://dx.doi.org/10.23939/fortifications2022.16.091.

Full text
Abstract:
The following article is the first attempt to analyze and systematize the sculptural images of St. John of Nepomuk in the late XVIII-XIX centuries in Galicia, determine the accurate location to suggest the authorship of the work and develop a restoration program to put into effect work on the monument. Having conducted a stylistic inquiry, we can say that the author was a sculptor Jan Nepomuckski from the village of Velyka Vyshenky. He was under the influence of such Lviv sculptors as Peter and Matthew Poleiowski. Compositional techniques, manner of interpretation of folds, and plasticity test
APA, Harvard, Vancouver, ISO, and other styles
17

Bedekovics, Tibor, William R. Taylor, Zhifu Sun, et al. "Abstract 2424: Detection of prostate cancer in urine by fragment-level DNA methylation analysis." Cancer Research 84, no. 6_Supplement (2024): 2424. http://dx.doi.org/10.1158/1538-7445.am2024-2424.

Full text
Abstract:
Abstract Introduction: Screening for prostate cancer (PCa) with molecular markers is hindered by low tumor allele fraction (TAF) in liquid biopsy samples such as blood or urine. Others have suggested that tumor allele enrichment can be achieved by evaluating fragment-level methylation patterns generated by next generation sequencing (NGS). Here, we test this concept using target capture NGS on cfDNA from prediagnostic collected urine samples to discriminate PCa from otherwise healthy men. Methods: Buffered urines were collected from 23 patients with biopsy confirmed PCa (Gleason score 6-9) and
APA, Harvard, Vancouver, ISO, and other styles
18

Lugo, Sofia A., Christopher Leon, Matthew A. Gladstone, et al. "Abstract C168: Developing lung adenocarcinoma cell lines to mitigate lung cancer health disparities." Cancer Epidemiology, Biomarkers & Prevention 33, no. 9_Supplement (2024): C168. http://dx.doi.org/10.1158/1538-7755.disp24-c168.

Full text
Abstract:
Abstract Lung cancer continues to be the number one cause of cancer-related deaths worldwide and remains a prominent source of cancer health disparities. Black/African American (B/AA) males exhibit a 12% higher lung cancer incidence rate and a 15% higher lung cancer death rate when compared to white males. Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer in all ethnic/racial groups, including B/AAs. To further examine this phenomenon, we want to create a collection of lung cancer cell lines that would be useful for molecular studies of lung cancer development,
APA, Harvard, Vancouver, ISO, and other styles
19

Luschnig, Cecelia Eaton. "(D.) Arnson Svarlien (trans.) Euripides: Ion, Helen, Orestes. Introduction and Notes by Matthew Wright. Pp. xlvi + 312, maps. Indianapolis and Cambridge: Hackett Publishing Company, Inc, 2016. Paper, £10.99, US$13 (Cased, £33.50, US$39.95). ISBN: 978-1-62466-480-9 (978-1-62466-481-6 hbk)." Classical Review 67, no. 2 (2017): 568–69. http://dx.doi.org/10.1017/s0009840x17000609.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Yadon, A., D. Ruelas, G. Min-Oo, J. Taylor, and M. R. Warr. "AB0108 IRAK4 INHIBITION SUPPRESSES PROINFLAMMATORY CYTOKINE PRODUCTION FROM HUMAN MACROPHAGES STIMULATED WITH SYNOVIAL FLUID FROM RHEUMATOID ARTHRITIS PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1353.2–1353. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3793.

Full text
Abstract:
Background:Rheumatoid arthritis (RA) is characterized by chronic, uncontrolled joint inflammation and tissue destruction. Macrophages are thought to be key mediators in both the initiation and perpetuation of this pathology.1,2The RA synovium contains a complex inflammatory milieu that can stimulate macrophage-dependent production of proinflammatory cytokines through multiple signaling pathways.1,2Existing evidence indicates that toll-like receptors (TLRs) and interleukin-1 receptors (IL-1R) along with their agonists, damage-associated molecular patterns (DAMPs) and IL-1β, are highly expressed
APA, Harvard, Vancouver, ISO, and other styles
21

Taraba, Jodi, Kavya Swarna, Allison Golbach, et al. "Abstract P3-23-05: Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients." Cancer Research 82, no. 4_Supplement (2022): P3–23–05—P3–23–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-23-05.

Full text
Abstract:
Abstract Background: Cyclin dependent kinase (CDK) 4/6 inhibitors (CDK 4/6i) can improve outcomes in ER-positive/HER2-negative (ER+/HER2-) breast cancer. The choice of CDK 4/6i selection and dose depends on clinical context and/or potential side effect of profile of each unique CDK 4/6i. The objective of this study was to evaluate practice patterns in patients initiated on CDK 4/6i and assess adherence to recommended laboratory monitoring in breast cancer patients in both an institutional and national dataset. Methods: The institutional cohort (IC) involved a retrospective chart review of pati
APA, Harvard, Vancouver, ISO, and other styles
22

Kong, Tim, Alex Mabry, Jingqin Luo, et al. "Abstract PS12-03: Molecular characterization of the NeoPalAna Endocrine Resistant (ET-R) Cohort: implications for CDK4/6 inhibitor (CDK4/6i) and ET resistance mechanisms in primary estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)." Clinical Cancer Research 31, no. 12_Supplement (2025): PS12–03—PS12–03. https://doi.org/10.1158/1557-3265.sabcs24-ps12-03.

Full text
Abstract:
Abstract Background: Resistance to ET is a major contributor to BC mortality. CDK4/6i overcomes ET-R. However, some ER+/HER2- BC are intrinsically resistant to ET/CDK4/6i. Here we report the primary endpoint of complete cell cycle arrest (CCCA) and correlative studies of the NeoPalAna (NCT01723774) ET-R Cohort to examine resistance biomarkers for palbociclib (PAL) + anastrozole (ANA). Methods: NeoPalAna is a multi-cohort single arm phase 2 neoadjuvant endocrine (NET) trial of PAL/ANA in clinical stage II/III ER+/HER2- BC. The ET-R Cohort enrolled patients (pts) with tumor Ki67 >10% afte
APA, Harvard, Vancouver, ISO, and other styles
23

Jesus, Rudvan Cicotti Alves de. "Psicologia Forense: pesquisa, prática clínica e aplicações." Revista Brasileira de Criminalística 9, no. 1 (2020): 81. http://dx.doi.org/10.15260/rbc.v9i1.375.

Full text
Abstract:
O livro “Psicologia Forense: pesquisa, prática clínica e aplicações” trata de uma obra inédita, no tocante que diz sobre o estudo da prática clinica a caracterizando de forma geral, sem dar ênfase a melhor, mas sim os condicionamentos para a prática em si.A obra foi elaborada por Matthew T. Huss que atualmente é professor de psicologia na Creighton University (Nebraska, EUA), ele também é autor de mais dois livros intitulados Psicologia Forense 1ª ed. (2008) e Psicologia Forense 2ª (2013).O livro é quase inexistente de ilustrações, uma vez que traz um conteúdo unicamente teórico e metodológico
APA, Harvard, Vancouver, ISO, and other styles
24

Lokaj, Rodney. "The Canticle of the Creatures as Hypotext behind Dante’s Pater Noster." Rocznik Filozoficzny Ignatianum 26, no. 2 (2021): 19–40. http://dx.doi.org/10.35765/rfi.2020.2602.3.

Full text
Abstract:
The article analyses Dante’s explanatory paraphrase and exegesis of the Lord’s Prayer, which opens the eleventh canto (v. 1–24) of Purgatory. The author reminds us that the prayer is the only one fully recited in the entire Comedy and this devotional practice is in line with the Franciscan prescription to recite it in the sixth hour of the Divine Office when Christ died on the cross. The prayer is reported by the poet on the first terrace of Purgatory, where the proud and vainglorious must learn the virtue of humility, and therefore it symbolizes the perfect reciprocity between man and Godhead
APA, Harvard, Vancouver, ISO, and other styles
25

Gonzalez, Pedro, Urania Rappo, Jennifer McGregor, Lisa DiPompo-Day, and Matthew W. McCarthy. "279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry." Open Forum Infectious Diseases 7, Supplement_1 (2020): S140. http://dx.doi.org/10.1093/ofid/ofaa439.323.

Full text
Abstract:
Abstract Background Dalbavancin, a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. A total of 39 of 39 patients with baseline S aureus bacteremia from previous studies who received dalbavancin (1500 mg or 1000 mg followed by 500 mg 1 week later) had clearance of bacteremia (100%). We describe the clinical features and efficacy of dalbavancin in patients with bacteremia or endocarditis from a retrospective registry study of dalbavancin. Methods Dalvance
APA, Harvard, Vancouver, ISO, and other styles
26

Mezni, Amina, Matthew Hardy, Mariacristina Ciccioli, and Anne-Sophie Pailhes-Jimenez. "Abstract 969: Epithelial and mesenchymal CTC detection in triple negative breast cancer patients using ANGLE’s Parsortix®system." Cancer Research 82, no. 12_Supplement (2022): 969. http://dx.doi.org/10.1158/1538-7445.am2022-969.

Full text
Abstract:
Abstract Introduction: Isolation of circulating tumor cells (CTCs) is widely recognised as a prognostic biomarker in metastatic breast cancer. Recently, it was shown that CTC clearance following specific therapies may predict chemosensitivity in triple negative breast cancer (TNBC) patients. However, a limited amount of CTC research is available in TNBC due to the inability of epitope-dependent CTC platforms to capture CTCs in a sufficient proportion of patients, especially when evaluating non-metastatic patients (Stage I-III). ANGLE has developed a Research Use Only (RUO) workflow including t
APA, Harvard, Vancouver, ISO, and other styles
27

Goetz, Matthew, Seth Wander, Thomas Bachelot, et al. "Abstract PO1-18-12: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation." Cancer Research 84, no. 9_Supplement (2024): PO1–18–12—PO1–18–12. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-18-12.

Full text
Abstract:
Abstract Background: Patients with estrogen receptor-positive (ER+) metastatic breast cancer (BC) may develop resistance to endocrine therapy (ET), particularly following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), potentially driven by a mutation in the ERa-coding gene, ESR1. Lasofoxifene, an oral, next-generation ET and ER breast antagonist, had potent activity in mBC xenograft models expressing ESR1 mutations, either as a single agent or combined with a CDK4/6i. Subsequently, two phase 2 studies evaluated lasofoxifene in women with ER+/HER2- metastatic BC and an ESR1 m
APA, Harvard, Vancouver, ISO, and other styles
28

O'Sullivan, Ciara C., Jun He, Jason Sinnwell, et al. "Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)." Cancer Research 82, no. 4_Supplement (2022): P5–13–22—P5–13–22. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-22.

Full text
Abstract:
Abstract Background: Cyclin dependent 4/6 kinase inhibitors (CDK4/6i) and endocrine therapy (ET) have improved progression-free survival (PFS) and overall survival in HR+ MBC, but progression of disease ultimately occurs. Apart from HR+ status, there are no clinically available biomarkers that enable oncologists to determine prognosis and predict response to CDK4/6i. An emerging biomarker is serum thymidine kinase 1 (TK1), a secreted marker of proliferation that is prognostic in pts with HR+ HER2- MBC. High levels of TKa are associated with inferior PFS, whereas pts with low TKa levels pretrea
APA, Harvard, Vancouver, ISO, and other styles
29

Lalanne, Ana, Camille Jamet, Christian H. Ottensmeier, et al. "Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer." Cancer Research 83, no. 8_Supplement (2023): LB205. http://dx.doi.org/10.1158/1538-7445.am2023-lb205.

Full text
Abstract:
Abstract Background: Head and Neck (HNSCC) and Ovarian cancer (OC) are two indications for which immunotherapy had limited impact so far. Current treatments achieve high rates of initial success through surgery and adjuvant chemo/radiotherapy, but patients (pts) remain at high risk of relapse in both indications. Immune stimulation using a vaccine is a promising strategy to a clinically meaningful improvement. Herein we report phase I data of TG4050, a vaccine engineered to carry a pt tailored antigen payload, in pts with HNSCC (NCT04183166) or OC (NCT03839524). Methods: Tumor specific variant
APA, Harvard, Vancouver, ISO, and other styles
30

Schneider, Jennifer L., Blake Locher, Jennifer S. Rivelli, et al. "Abstract C073: Enhancing cancer care: Insights from the CAFÉ Trial on Financial Navigation and program improvements." Cancer Epidemiology, Biomarkers & Prevention 33, no. 9_Supplement (2024): C073. http://dx.doi.org/10.1158/1538-7755.disp24-c073.

Full text
Abstract:
Abstract Purpose: Cancer-related financial hardship is prevalent and associated with poor health outcomes. CAFÉ is a multi-site randomized control trial (RCT) testing a financial navigation intervention to reduce financial hardship for people newly diagnosed with cancer. Methods: The CAFÉ trial randomized participants to usual care or one of two intervention arms. Participants randomized to the intervention arms received either brief (one proactive outreach) or extended (three proactive outreaches) contact from a navigator to assess for financial concerns. Navigation services lasted for 6 mont
APA, Harvard, Vancouver, ISO, and other styles
31

Lugo, Sofia, Christopher Leon, Matthew Gladstone, et al. "Abstract 1004: Establishing lung adenocarcinoma cell lines to mitigate lung cancer health disparities." Cancer Research 84, no. 6_Supplement (2024): 1004. http://dx.doi.org/10.1158/1538-7445.am2024-1004.

Full text
Abstract:
Abstract Lung cancer remains the leading cause of cancer death worldwide and is a pronounced source of cancer health disparities. Black/African American (B/AA) individuals demonstrate the highest lung cancer death rates when compared to other ethnic/racial groups. B/AA males exhibit a 15% higher lung cancer death rate and a 12% higher lung cancer incidence when compared to White males. Lung adenocarcinoma (LUAD) is the most common histological subtype in all races including B/AA. To study lung cancer and its related disparities, essential tools such as lung cancer cell lines are important; the
APA, Harvard, Vancouver, ISO, and other styles
32

Chumsri, Saranya, Sharmila Giri, Andy J. Ness, et al. "Abstract 5005: Safety and tolerability of multi-epitope HER2 peptide vaccines in combination with trastuzumab emtansine in HER2-positive breast cancer patients with residual disease after neoadjuvant chemotherapy." Cancer Research 84, no. 6_Supplement (2024): 5005. http://dx.doi.org/10.1158/1538-7445.am2024-5005.

Full text
Abstract:
Abstract Background: Residual disease after neoadjuvant chemotherapy (NAC) in breast cancer (BC) confers poor outcomes. Trastuzumab emtansine (T-DM1) is approved for HER2+ patients with residual disease after NAC. However, many patients still develop recurrence. H2NVAC is a multi-epitope CD4 helper T cell activating vaccine that includes a pool of 4 degenerate HER2-derived HLA-DR epitopes admixed with GM-CSF. Our previous phase I trial showed that this vaccine was safe and generated robust, long-lasting T and B cell immune responses. Method: We conducted a safety run-in phase of H2NVAC in comb
APA, Harvard, Vancouver, ISO, and other styles
33

Lindsay, L., H. A. Mao, J. E. Cheng, et al. "POS0792 BASELINE FACTORS ASSOCIATED WITH LUPUS FLARES: A POST-HOC ANALYSIS OF PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS ENROLLED IN A 48 WEEK PHASE II RANDOMIZED CLINICAL TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 648.2–648. http://dx.doi.org/10.1136/annrheumdis-2021-eular.4042.

Full text
Abstract:
Background:Systemic lupus erythematosus (SLE) is a chronic disease characterized by periodic flares associated with poor outcomes and subsequent organ damage (1-2). Flare prevention is important for optimal patient management and development of effective therapies.Objectives:To identify patient-level factors associated with flares among patients with moderate/severe SLE.Methods:We conducted a post-hoc analysis of 260 patients with active, autoantibody+ SLE enrolled in a phase II randomized clinical trial (Fenebrutinib) (3). The relationship between baseline demographic (age, gender, ethnicity,
APA, Harvard, Vancouver, ISO, and other styles
34

Clemente, Leticia Campos, Omar Alhalabi, Matthew T. Campbell, et al. "Abstract 7523: An integrated analysis of radiologic and pathological responses in patients with metastatic renal cell carcinoma who presented with primary renal tumor in situ and received first-line nivolumab plus ipilimumab followed by cytoreductive nephrectomy." Cancer Research 84, no. 6_Supplement (2024): 7523. http://dx.doi.org/10.1158/1538-7445.am2024-7523.

Full text
Abstract:
Abstract Background: The decision to perform cytoreductive nephrectomy (CN) and timing of CN in patients (pts) with metastatic renal cell carcinoma (mRCC) and primary who respond to immune checkpoint therapy (ICT) is a matter of debate. In CheckMate-214, nivolumab plus ipilimumab (N+I) yielded a 35% objective response rate in the primary; however, there is a paucity of pathological data from nephrectomy specimens (Nx) after treatment with N+I. We sought to investigate the radiologic and pathological responses and correlate the findings with outcomes in pts receiving 1L N+I followed by CN. Meth
APA, Harvard, Vancouver, ISO, and other styles
35

O'Sullivan, Ciara, Karla V. Ballman, Linda M. McCall, et al. "Abstract P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–10–19—P2–10–19. https://doi.org/10.1158/1557-3265.sabcs24-p2-10-19.

Full text
Abstract:
Abstract Background: Patients with HER2+ early breast cancer (EBC) and invasive residual disease (RD) after neoadjuvant therapy (NAT) have a higher risk of relapse than patients who have a pathologic complete response (pCR). Escalation of therapy in patients with RD using post-neoadjuvant T-DM1 has become the new standard of care, leading to improved invasive disease-free survival (iDFS), but patients with estrogen receptor (ER)-negative or nodal RD have suboptimal outcomes, and central nervous system recurrences are a challenge. More effective treatment strategies are urgently needed. A011801
APA, Harvard, Vancouver, ISO, and other styles
36

Li, Xiao-Hua, Benjamin Goldenson, Jaya Lakshmi Thangaraj, et al. "Abstract 559: Targeting hematological malignancies and solid tumors with switchable chimeric antigen receptor-engineered iPSC-derived natural killer cells." Cancer Research 82, no. 12_Supplement (2022): 559. http://dx.doi.org/10.1158/1538-7445.am2022-559.

Full text
Abstract:
Abstract Switchable chimeric antigen receptors (sCAR) provide an important new strategy to precisely regulate CAR-mediated anti-tumor activity. The sCAR system combines a CAR that recognizes peptide neoepitope (PNE) with an injectable “switch” molecule that consists of an anti-tumor Fab linked to PNE. Configurating PNE at different location or chain of the Fab enables us to identify best switches optimal for tumor targeting. Previous studies demonstrate that this sCAR system expressed in T cells provides tight control over anti-tumor activity. Here, we translated this approach to engineer natu
APA, Harvard, Vancouver, ISO, and other styles
37

McMillan, Elizabeth A., Carine Bossard, Emily Creger, et al. "Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models." Cancer Research 82, no. 12_Supplement (2022): 3928. http://dx.doi.org/10.1158/1538-7445.am2022-3928.

Full text
Abstract:
Abstract Dysregulated alternative pre-mRNA splicing (AS) is commonly associated with human malignancies, producing pathological proteomes that underlie disease initiation, progression, and therapeutic resistance. The CDC2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs) are thought to govern AS efficiency and specificity by directly phosphorylating splicing factors that influence pre-mRNA splice junction selection. Cirtuvivint (SM08502) is a first-in-class small molecule ATP-competitive inhibitor of CLK/DYRK kinases. To evaluate the contribution of these kinases to A
APA, Harvard, Vancouver, ISO, and other styles
38

Premji, Sarah K., Tanmayi S. Pai, Savannah S. Liddell, et al. "Abstract P1-11-08: Practice patterns and uptake of adjuvant abemaciclib in high risk localized hormone receptor positive, HER2-negative breast cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P1–11–08—P1–11–08. https://doi.org/10.1158/1557-3265.sabcs24-p1-11-08.

Full text
Abstract:
Abstract Introduction: In MonarchE, two years of adjuvant abemaciclib combined with endocrine therapy (ET) improved invasive disease-free survival and distant relapse free survival, with recent data confirming continued benefit beyond the two-year treatment period. The FDA approved abemaciclib in October 2021 in patients (pts) with HR+, HER2- early breast cancer (EBC) with node positive and Ki-67 ≥20%, based on an unplanned MonarchE analysis. The approval was amended in March 2023 to revert back to the intention to treat (ITT) protocol, including ≥4 axillary lymph nodes (ALN) or 1-3 ALN with s
APA, Harvard, Vancouver, ISO, and other styles
39

Marsal, S., H. Corominas, J. J. De Agustin, et al. "AB0264 1-YEAR RESULTS OF A NON-INVASIVE AURICULAR VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1158.2–1159. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2628.

Full text
Abstract:
Background:Despite the clinical benefits of current pharmacological treatments for rheumatoid arthritis (RA), there remains an unmet need for alternative treatment approaches. Initial results of a 12-week proof-of-concept study of non-invasive, vagus nerve stimulation (VNS) of the auricular branch of the vagus nerve from a wearable device to treat RA showed the device to be well-tolerated with significant reductions in the DAS28-CRP and RA disease severity1.Objectives:This analysis presents data from the 9-month extension of the original proof-of-concept study.Methods:Following the completion
APA, Harvard, Vancouver, ISO, and other styles
40

Zhang, Kevin, Matthew Rees, Mahsa Khanlari, Laura Rooms, Raul Ribeiro, and Marcin Wlodarski. "Abstract A38: Pediatric Germline CSF3R T618I mutation gives insight into disease progression and long-term therapy options of Chronic Neutrophilic Leukemia." Blood Cancer Discovery 4, no. 3_Supplement (2023): A38. http://dx.doi.org/10.1158/2643-3249.aml23-a38.

Full text
Abstract:
Abstract Chronic Neutrophilic Leukemia (CNL) is a rare BCR-ABL negative myeloproliferative neoplasm that affects approximately 1 in a million individuals. The typical age of onset and disease presentation is in elderly patients with a median age of 63 and a range of 9-84. The oncogenic driver of CSF3R, the G-CSF receptor protein, in CNL has been classified over the last decade and has improved therapies for patients with targeted Tyrosine Kinase Inhibitors, such as Ruxolitinib (a potent JAK1/2 inhibitor). Currently, the only curative option is an allogeneic hemopoietic stem cell transplant wit
APA, Harvard, Vancouver, ISO, and other styles
41

Kumar, Praveen Kumar Raj, Jianfang Liu, Anthony Soltis, et al. "Abstract PO3-13-10: Proteogenomic characterization of primary invasive breast tumors from young women compared to matched tumors from older women." Cancer Research 84, no. 9_Supplement (2024): PO3–13–10—PO3–13–10. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-13-10.

Full text
Abstract:
Abstract Introduction: Breast cancer (BC) in women < 40 years old accounts for ~5% of BC diagnosed in the U.S. However, young women have more aggressive tumors and worse outcomes, including higher rates of recurrence and lower disease-free and overall survival, compared to older women. To better understand mechanisms for these disparities, an integrated proteogenomic study of tumors from young (< 40) and older (≥ 60) women was performed through the Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) program. Methods: 34 pairs of retrospectively collected, untreat
APA, Harvard, Vancouver, ISO, and other styles
42

Jelic, Monika, Meghan Birkholz, Matthew Webber, et al. "Improving the Culture Surrounding Tracheal Aspirates in Mechanically Ventilated Children." Journal of the Pediatric Infectious Diseases Society 13, Supplement_3 (2024): S12. https://doi.org/10.1093/jpids/piae088.023.

Full text
Abstract:
Abstract Corresponding Author: Monika Jelic, Pediatric Infectious Diseases, Children’s Hospital Colorado, 13123 East 16th Avenue, Box 055, Aurora, CO 80045, Phone: 720-777-6605, monika.jelic@childrenscolorado.org Alternate Corresponding Author: Sarah Parker, Pediatric Infectious Disease, Children’s Hospital Colorado, 13123 East 16th Avenue, Box 055, Aurora, CO 80045, Phone: 720-777-8811, sarah.parker@childrenscolorado.org Funding/Support: This study was supported by University of Colorado Institute for Healthcare Quality, Safety and Efficiency (IHQSE) Clinical Effectiveness and Patient Safety
APA, Harvard, Vancouver, ISO, and other styles
43

Tedeschi, Antonio, David H. Peng, Fiorella Schischlik, et al. "Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications." Cancer Research 84, no. 6_Supplement (2024): 3317. http://dx.doi.org/10.1158/1538-7445.am2024-3317.

Full text
Abstract:
Abstract Alterations in KRAS are a main cancer driver. Amplifications of the KRAS wild-type (wt) allele account for ~7% of all KRAS-driven cancers and are frequent in gastric (~5%), esophageal (~13%) and gastroesophageal junction cancers (~12%). KRASG12V mutations account for ~28% of pancreatic cancers, 9% of colorectal cancers and 6% of lung adenocarcinoma. There is an urgent medical need to identify targeted therapies for these frequent KRAS alterations. Herein, we describe BI 3706674, a novel, potent and orally bioavailable small molecule inhibitor of the KRAS oncogene for clinical testing
APA, Harvard, Vancouver, ISO, and other styles
44

Giridhar, Karthik, Amrit Singh, Eyad Al-Hattab, et al. "Abstract P3-07-29: ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells in Metastatic Breast Cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P3–07–29—P3–07–29. https://doi.org/10.1158/1557-3265.sabcs24-p3-07-29.

Full text
Abstract:
Abstract Introduction: The FDA-cleared CellSearch® Circulating Tumor Cell (CTC) assay is a non-invasive liquid biopsy approved for metastatic disease monitoring. In metastatic breast cancer (MBC), prospective phase III data supports a positivity threshold of ≥5 CTC. Positive CTCs (≥5 CTCs) at baseline (BL), persistent CTC positivity, and increases in CTC count over time outperform serum tumor markers such as CA 27-29 and CA 15-3 and predict radiographic disease progression. Nevertheless, CTC enumeration has not been utilized broadly in real-world clinical practice. Therefore, we sought to eval
APA, Harvard, Vancouver, ISO, and other styles
45

Leon-Ferre, Roberto A., Sarah Flora Jonas, Roberto Salgado, et al. "Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients." Cancer Research 83, no. 5_Supplement (2023): PD9–05—PD9–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd9-05.

Full text
Abstract:
Abstract Background: The prognostic value of stromal tumor-infiltrating lymphocytes (TILs) as a biomarker for triple-negative breast cancer (TNBC) has been extensively demonstrated in patients (pts) receiving (neo)adjuvant systemic therapy. In addition, several small studies suggest that a subset of pts with early-stage TNBC and high TILs have excellent long-term outcomes, even in the absence of systemic therapy [1-3]. However, data on the absolute risk of TNBC recurrence according to TIL levels in the absence of systemic therapy are limited and critical to inform the design of future systemic
APA, Harvard, Vancouver, ISO, and other styles
46

Mehta, Pallavi, Aakanksha A. Singh, Neha Yadav, et al. "Busulfan (Bu) and Cyclophosphamide (Cy) Based Conditioning Regimen Still Holds the Promise of Being a Safe and Efficacious Regimen for Allogeneic Transplantation in Patients with Transfusion Dependent Thalassemia (TDT) Even in High Risk." Blood 138, Supplement 1 (2021): 949. http://dx.doi.org/10.1182/blood-2021-150358.

Full text
Abstract:
Abstract Introduction: Allogeneic stem cell transplantation (HSCT) is a potential curative treatment for TDT. BuCy based regimen has been used widely as a standard myeloablative chemotherapy. However, the use of treosulfan based conditioning regimen has increased over the last decade (Choudhary D et al BBMT 2013). We analysed the safety and efficacy of BuCy based vs Treosulfan/Thiotepa/Fludrabine (Treo/Thio/Flu) regimens in TDT between September 2013 and March 2021. Method: This is an observational retrospective hospital record-based study approved by Institutional Review Board. Regimen used:
APA, Harvard, Vancouver, ISO, and other styles
47

Damodaran, Senthil, Massimo Cristofanilli, Matthew Goetz, et al. "Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study." Cancer Research 84, no. 9_Supplement (2024): PO2–14–09—PO2–14–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-14-09.

Full text
Abstract:
Abstract Introduction: Estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancers commonly acquire constitutively active mutations in the ERα-encoding gene (ESR1), resulting in endocrine therapy (ET) resistance. In the phase 2, ELAINE 2 study (NCT04432454), LAS (a breast ER antagonist) combined with Abema provided a median progression-free survival (PFS) of ~13 months (mos) and clinical benefit rate (CBR) of 66% in patients with endocrine-resistant, ER+/HER2- mBC and ESR1 mutations (mESR1; Damodaran. J Clin Oncol 2023;41:suppl16;1057). Our objective was to describe baseline genomic
APA, Harvard, Vancouver, ISO, and other styles
48

Schenck, Desiree, Rita Zhou, Alexis Mantilla, et al. "Abstract 1238: Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients." Cancer Research 82, no. 12_Supplement (2022): 1238. http://dx.doi.org/10.1158/1538-7445.am2022-1238.

Full text
Abstract:
Abstract Neoantigen directed immunotherapy holds promise to increase the likelihood of patients with solid tumor devoid of immune infiltration benefiting from immune checkpoint immunotherapy (CPI). A heterologous prime-boost vaccination approach consisting of Chimpanzee Adenovirus (ChAd) prime and multiple self-amplifying mRNA (SAM) boosts, delivering 20 neoantigens, has been evaluated in a Phase 1/2 clinical trial in late-stage solid tumor patients in combination with nivolumab and ipilimumab (NCT03639714). Neoantigen dynamics, tumor burden and genomic correlates of response were studied over
APA, Harvard, Vancouver, ISO, and other styles
49

Parakrama, Ruwan, Baho Sidiqi, Lyudmyla Demyan, et al. "Abstract A022: Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient outcomes and successful completion of NAT." Cancer Research 82, no. 22_Supplement (2022): A022. http://dx.doi.org/10.1158/1538-7445.panca22-a022.

Full text
Abstract:
Abstract Optimal management of patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC) is controversial and variation exists within/across academic and healthcare systems. Herein we describe the initial results of a neoadjuvant therapy (NAT) pathway across one of New York’s largest, most diverse health care systems. The NATP was established at Northwell Health in June 2019, consisting of an initial, single-day pancreas multi-disciplinary clinic (PMDC) visit, followed by NAT, interval scans and PMDC re-reviews at two and four months, prior to consideration of radiation and
APA, Harvard, Vancouver, ISO, and other styles
50

Adams, MacKenzie, Charmi Trivedi, Sapana Gupta, et al. "Abstract 5818: Incidence and management of steroid-refractory immune checkpoint inhibitor pneumonitis: a single-center retrospective analysis." Cancer Research 85, no. 8_Supplement_1 (2025): 5818. https://doi.org/10.1158/1538-7445.am2025-5818.

Full text
Abstract:
Abstract Introduction: Pneumonitis is a serious and potentially lethal complication of treatment with immune checkpoint inhibitors (ICI). In a rare subset of patients, front-line treatment with steroids is ineffective, necessitating a second-line steroid-sparing agent. We conducted a single-center, retrospective analysis of patients treated with ICIs to determine incidence and outcome patterns of patients who develop pneumonitis. Methods: We conducted manual chart review on a cohort of 2, 820 patients treated with ICIs at our institution from 2015 to 2024. Steroid-refractory pneumonitis was de
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography